首页 > 最新文献

Histopathology最新文献

英文 中文
STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours STK11 (LKB1) 免疫组化是 STK11 附件肿瘤敏感而特异的标记物。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-21 DOI: 10.1111/his.15303
Amir Dehghani, Aarti E Sharma, Stephanie E Siegmund, Chrystalle K Carreon, Colin J R Stewart, Fabiola Medeiros, Jelena Mirkovic, Marisa R Nucci, Christopher P Crum, Jason L Hornick, Brooke E Howitt, W Glenn McCluggage, David L Kolin

Aims

STK11 adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz–Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: ‘ST11’ in preceding sentence has been corrected to ‘STK11’ in this version.] It predominantly originates from the para-adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. STK11 adnexal tumours have a broad differential diagnosis due to their variable morphology and non-specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an STK11 mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of STK11 adnexal tumours and morphological mimics.

Methods and results

IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli–Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra-ovarian sex cord-stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo-ovarian high-grade serous carcinomas, five ovarian mesonephric-like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high-grade serous carcinoma with subclonal loss.

Conclusions

STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context.

目的:ST11 附件肿瘤是最近描述的一种罕见恶性肿瘤,与 Peutz-Jeghers 综合征有关。它主要起源于附件旁软组织,通常继发于输卵管和卵巢。STK11 附件肿瘤由于其形态多变和非特异性免疫特征而具有广泛的鉴别诊断,目前确诊需要通过测序来确定 STK11 基因突变。我们研究了STK11(LKB1)免疫组化(IHC)在一组STK11附件肿瘤和形态学模拟物中的诊断效用:对122例肿瘤进行了STK11免疫组化,其中包括17例STK11附件肿瘤和105例形态学拟态肿瘤(10例沃尔夫源性女性附件肿瘤、22例成人颗粒细胞瘤、10例幼年颗粒细胞瘤、4例Sertoli-Leydig细胞瘤、2例Leydig细胞瘤、1例Sertoli细胞瘤、1例类固醇细胞瘤、4例卵巢外性索状细胞瘤)、4例卵巢外性索间质瘤、16例卵巢子宫内膜样癌、8例输卵管卵巢高级别浆液性癌、5例卵巢间质样腺癌、14例卵巢癌肉瘤、5例腹膜恶性间皮瘤、2例盆腔丛状子宫肌瘤和1例卵巢实性假乳头状瘤)。所有 STK11 附件肿瘤的 STK11 细胞质染色均完全消失。所有其他类型的肿瘤都显示保留了细胞质染色,只有一种粘液分化的子宫内膜样癌显示 STK11 表达完全丧失,一种高级别浆液性癌显示亚克隆丧失:STK11是一种高度敏感且特异的免疫组化标记物,可用于区分STK11附件肿瘤及其组织学模拟物,并可避免在适当的形态学背景下进行确证性分子研究。
{"title":"STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours","authors":"Amir Dehghani,&nbsp;Aarti E Sharma,&nbsp;Stephanie E Siegmund,&nbsp;Chrystalle K Carreon,&nbsp;Colin J R Stewart,&nbsp;Fabiola Medeiros,&nbsp;Jelena Mirkovic,&nbsp;Marisa R Nucci,&nbsp;Christopher P Crum,&nbsp;Jason L Hornick,&nbsp;Brooke E Howitt,&nbsp;W Glenn McCluggage,&nbsp;David L Kolin","doi":"10.1111/his.15303","DOIUrl":"10.1111/his.15303","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p><i>STK11</i> adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz–Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: ‘<i>ST11</i>’ in preceding sentence has been corrected to ‘<i>STK11</i>’ in this version.] It predominantly originates from the para-adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. <i>STK11</i> adnexal tumours have a broad differential diagnosis due to their variable morphology and non-specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an <i>STK11</i> mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of <i>STK11</i> adnexal tumours and morphological mimics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>IHC for STK11 was performed on 122 tumours, including 17 <i>STK11</i> adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli–Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra-ovarian sex cord-stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo-ovarian high-grade serous carcinomas, five ovarian mesonephric-like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All <i>STK11</i> adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high-grade serous carcinoma with subclonal loss.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing <i>STK11</i> adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 5","pages":"769-782"},"PeriodicalIF":3.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NTRK fusion cervical sarcoma with rhabdoid cells and misleading molecular testing 带有横纹肌细胞的 NTRK 融合型颈椎肉瘤和误导性分子检测。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-21 DOI: 10.1111/his.15306
Connor Thellman, Kevin C Halling, Ozlen Saglam
{"title":"NTRK fusion cervical sarcoma with rhabdoid cells and misleading molecular testing","authors":"Connor Thellman,&nbsp;Kevin C Halling,&nbsp;Ozlen Saglam","doi":"10.1111/his.15306","DOIUrl":"10.1111/his.15306","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 6","pages":"959-961"},"PeriodicalIF":3.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes. E-cadherin 染色在乳腺小叶肿瘤与导管肿瘤诊断中的应用:皇帝没有穿衣服。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-13 DOI: 10.1111/his.15295
Seyed R Taha, Fouad Boulos

Categorizing breast neoplasia as ductal or lobular is a daily exercise that relies on a combination of histologic and immunohistochemical tools. The historically robust link between loss of the E-cadherin molecule and lobular neoplasia has rendered staining for E-cadherin by immunohistochemistry a staple of this diagnostic process. Unfortunately, discordances between E-cadherin expression and histomorphology, and variations in E-cadherin staining patterns and intensities abound in clinical practice, but are often neglected in favour of a binary interpretation of the E-cadherin result. In this article, we highlight the complexities of E-cadherin expression through a review of the E-cadherin protein and its associated gene (CDH1), the mechanisms leading to aberrant/absent E-cadherin expression, and the implications of these factors on the reliability of the E-cadherin immunohistochemical stain in the classification of ductal versus lobular mammary neoplasia.

将乳腺肿瘤分为导管型和小叶型是一项日常工作,需要综合运用组织学和免疫组化工具。E-cadherin分子的缺失与乳腺小叶肿瘤之间历来存在密切联系,因此免疫组化法对E-cadherin进行染色已成为诊断过程中的主要方法。遗憾的是,在临床实践中,E-cadherin表达与组织形态学之间的不一致性、E-cadherin染色模式和强度的差异比比皆是,但却常常被忽视,而倾向于对E-cadherin结果进行二元解释。在本文中,我们通过回顾 E-cadherin蛋白及其相关基因(CDH1)、导致E-cadherin表达异常/缺失的机制,以及这些因素对E-cadherin免疫组化染色在乳腺导管性与小叶性肿瘤分类中的可靠性的影响,强调了E-cadherin表达的复杂性。
{"title":"E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.","authors":"Seyed R Taha, Fouad Boulos","doi":"10.1111/his.15295","DOIUrl":"https://doi.org/10.1111/his.15295","url":null,"abstract":"<p><p>Categorizing breast neoplasia as ductal or lobular is a daily exercise that relies on a combination of histologic and immunohistochemical tools. The historically robust link between loss of the E-cadherin molecule and lobular neoplasia has rendered staining for E-cadherin by immunohistochemistry a staple of this diagnostic process. Unfortunately, discordances between E-cadherin expression and histomorphology, and variations in E-cadherin staining patterns and intensities abound in clinical practice, but are often neglected in favour of a binary interpretation of the E-cadherin result. In this article, we highlight the complexities of E-cadherin expression through a review of the E-cadherin protein and its associated gene (CDH1), the mechanisms leading to aberrant/absent E-cadherin expression, and the implications of these factors on the reliability of the E-cadherin immunohistochemical stain in the classification of ductal versus lobular mammary neoplasia.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subungual melanoma: molecular analysis of 31 cases from early stage to invasive melanoma. 舌下黑色素瘤:从早期黑色素瘤到浸润性黑色素瘤的 31 个病例的分子分析。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-13 DOI: 10.1111/his.15297
Christophe Perrin, Michael Coutts, Bérengère Dadone-Montaudié

Aims: The distinction between the benign subungual melanocytic lesions and an early lesion of subungual melanoma (SUM) remains a diagnostic challenge. We evaluated the routine diagnostic utility of array Comparative Genomic Hybridization (aCGH) to detect whole-genome copy number variations (CNV) as well as targeted next-generation sequencing (NGS) in SUM.

Methods and results: This retrospective study included 20 cases of in situ SUM and 11 cases of invasive SUM. Analysis by aCGH detected common oncogene amplifications in all but one case of invasive SUM (n = 10) and in all cases of in situ SUM with a melanocyte count (MC) >45/mm (n = 4 true positive) and the average number of CNV was 8.5. Thirteen remaining cases of in situ SUM gave false negative results (n = 13), owing to a lack of sufficient melanocytes to analyse (median MC of 35.35; range: 10.16-39.5). Molecular analysis failed in four cases (three in situ SUM and one invasive SUM) due to insufficient amounts of DNA. Across the whole cohort, the sensitivity of aCGH was 52%, but when adjusting the cutoff to MC >45/mm, the sensitivity was 93%. Targeted NGS was less informative than aCGH analyses in our series of SUM.

Conclusion: To distinguish malignant from benign lesions, especially in situ SUM versus atypical lentiginous melanocytic proliferations, aCGH analysis should be performed when the MC is above 45 melanocytes per linear millimetre. This pangenomic method can detect oncogene amplifications, as well as a number of CNV >3, which strongly support the diagnosis of malignancy.

目的:如何区分良性舌下黑色素细胞病变和舌下黑色素瘤(SUM)早期病变仍是诊断难题。我们评估了阵列比较基因组杂交(aCGH)检测全基因组拷贝数变异(CNV)以及靶向下一代测序(NGS)在SUM中的常规诊断效用:这项回顾性研究包括 20 例原位 SUM 和 11 例浸润性 SUM。通过 aCGH 分析,除一例浸润性 SUM(n = 10)外,所有原位 SUM 均检测到常见的癌基因扩增,且黑色素细胞计数(MC)>45/mm(n = 4 例真阳性),CNV 的平均数目为 8.5。其余 13 例原位 SUM 由于缺乏足够的黑色素细胞进行分析,结果为假阴性(n = 13)(中位数 MC 为 35.35;范围:10.16-39.5)。四例病例(三例原位 SUM 和一例浸润性 SUM)的分子分析因 DNA 数量不足而失败。在整个队列中,aCGH 的灵敏度为 52%,但当将临界值调整为 MC >45/mm 时,灵敏度为 93%。在我们的 SUM 系列中,靶向 NGS 的信息量低于 aCGH 分析:结论:要区分恶性和良性病变,尤其是原位 SUM 和非典型皮损黑素细胞增生,应在 MC 超过 45 个黑素细胞/毫米时进行 aCGH 分析。这种泛基因组学方法可以检测到癌基因扩增以及CNV数目大于3的情况,从而有力地支持恶性肿瘤的诊断。
{"title":"Subungual melanoma: molecular analysis of 31 cases from early stage to invasive melanoma.","authors":"Christophe Perrin, Michael Coutts, Bérengère Dadone-Montaudié","doi":"10.1111/his.15297","DOIUrl":"https://doi.org/10.1111/his.15297","url":null,"abstract":"<p><strong>Aims: </strong>The distinction between the benign subungual melanocytic lesions and an early lesion of subungual melanoma (SUM) remains a diagnostic challenge. We evaluated the routine diagnostic utility of array Comparative Genomic Hybridization (aCGH) to detect whole-genome copy number variations (CNV) as well as targeted next-generation sequencing (NGS) in SUM.</p><p><strong>Methods and results: </strong>This retrospective study included 20 cases of in situ SUM and 11 cases of invasive SUM. Analysis by aCGH detected common oncogene amplifications in all but one case of invasive SUM (n = 10) and in all cases of in situ SUM with a melanocyte count (MC) >45/mm (n = 4 true positive) and the average number of CNV was 8.5. Thirteen remaining cases of in situ SUM gave false negative results (n = 13), owing to a lack of sufficient melanocytes to analyse (median MC of 35.35; range: 10.16-39.5). Molecular analysis failed in four cases (three in situ SUM and one invasive SUM) due to insufficient amounts of DNA. Across the whole cohort, the sensitivity of aCGH was 52%, but when adjusting the cutoff to MC >45/mm, the sensitivity was 93%. Targeted NGS was less informative than aCGH analyses in our series of SUM.</p><p><strong>Conclusion: </strong>To distinguish malignant from benign lesions, especially in situ SUM versus atypical lentiginous melanocytic proliferations, aCGH analysis should be performed when the MC is above 45 melanocytes per linear millimetre. This pangenomic method can detect oncogene amplifications, as well as a number of CNV >3, which strongly support the diagnosis of malignancy.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proof of concept that melanoma nuclear count compares favourably with the benchmark histological prognostic feature, Breslow thickness. 证明黑色素瘤核计数与组织学预后基准特征--布瑞斯洛厚度--相比具有优势。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-13 DOI: 10.1111/his.15300
Charlotte Gurr, Mark Bamford, Nicola Oswald, Louisa Udensi, Christopher Ready, Kritika Gupta, Tiffany Buhagiar, Gerald Saldanha

Aims: Breslow thickness (BT) is the most important histological prognostic feature for melanoma prognosis, but it only captures tumour size in one dimension. Adding a further measurement in a different axis has been shown to improve prognostic value. It seems reasonable that further prognostic value could be obtained by estimating the number of invasive melanoma cells using nuclear count. The aim of this study was to show proof of concept that nuclear count has prognostic value independent of BT.

Methods and results: Melanoma cell nuclei were labelled with SRY-related HMG-box 10 (SOX10) protein, the sections scanned and StarDist machine-learning algorithm used to count nuclei in 102 cases of primary cutaneous melanoma. Prognostic value was assessed using survival analyses. Nuclear count correlated strongly with T category, BT and calculated tumour area (each P < 0.001), suggesting that it was a valid marker of melanoma burden. Nuclear count was a predictor for overall survival in univariable analysis [hazard ratio (HR) = 2.25, confidence interval (CI) = 1.66-3.06, P < 0.001] and multivariable analysis (HR = 2.60, CI = 1.59-4.24, P < 0.001). BT and ulceration were significant in univariable analyses, but not in multivariable models with nuclear count. Models containing nuclear count showed the best fit. Similar results were seen for melanoma-specific and metastasis-free survival. Nuclear count was able to stratify melanomas within a given T stage.

Conclusions: This study demonstrated proof of concept that counting melanoma nuclei may be an improved measure of invasive tumour burden compared to BT. Future studies will need to refine methods of nuclear detection and also to confirm its prognostic value.

目的:布瑞斯洛厚度(BT)是黑色素瘤预后最重要的组织学预后特征,但它只能从一个维度反映肿瘤的大小。事实证明,在不同的轴上增加进一步的测量可提高预后价值。通过核计数估算浸润性黑色素瘤细胞的数量,似乎可以进一步提高预后价值。本研究旨在证明核计数具有独立于 BT 的预后价值:用 SRY 相关 HMG-box 10 (SOX10) 蛋白标记黑色素瘤细胞核,扫描切片,使用 StarDist 机器学习算法对 102 例原发性皮肤黑色素瘤细胞核进行计数。通过生存分析评估了预后价值。核计数与 T 类、BT 和计算出的肿瘤面积密切相关(各 P 结论):这项研究证明了一个概念,即与 BT 相比,黑色素瘤核计数可能是衡量浸润性肿瘤负荷的更好方法。今后的研究需要改进核检测方法,并确认其预后价值。
{"title":"Proof of concept that melanoma nuclear count compares favourably with the benchmark histological prognostic feature, Breslow thickness.","authors":"Charlotte Gurr, Mark Bamford, Nicola Oswald, Louisa Udensi, Christopher Ready, Kritika Gupta, Tiffany Buhagiar, Gerald Saldanha","doi":"10.1111/his.15300","DOIUrl":"https://doi.org/10.1111/his.15300","url":null,"abstract":"<p><strong>Aims: </strong>Breslow thickness (BT) is the most important histological prognostic feature for melanoma prognosis, but it only captures tumour size in one dimension. Adding a further measurement in a different axis has been shown to improve prognostic value. It seems reasonable that further prognostic value could be obtained by estimating the number of invasive melanoma cells using nuclear count. The aim of this study was to show proof of concept that nuclear count has prognostic value independent of BT.</p><p><strong>Methods and results: </strong>Melanoma cell nuclei were labelled with SRY-related HMG-box 10 (SOX10) protein, the sections scanned and StarDist machine-learning algorithm used to count nuclei in 102 cases of primary cutaneous melanoma. Prognostic value was assessed using survival analyses. Nuclear count correlated strongly with T category, BT and calculated tumour area (each P < 0.001), suggesting that it was a valid marker of melanoma burden. Nuclear count was a predictor for overall survival in univariable analysis [hazard ratio (HR) = 2.25, confidence interval (CI) = 1.66-3.06, P < 0.001] and multivariable analysis (HR = 2.60, CI = 1.59-4.24, P < 0.001). BT and ulceration were significant in univariable analyses, but not in multivariable models with nuclear count. Models containing nuclear count showed the best fit. Similar results were seen for melanoma-specific and metastasis-free survival. Nuclear count was able to stratify melanomas within a given T stage.</p><p><strong>Conclusions: </strong>This study demonstrated proof of concept that counting melanoma nuclei may be an improved measure of invasive tumour burden compared to BT. Future studies will need to refine methods of nuclear detection and also to confirm its prognostic value.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update of newly-recognized salivary gland neoplasms: molecular and immunohistochemical findings and clinical importance. 新认识的唾液腺肿瘤的更新:分子和免疫组化结果及临床重要性。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-07 DOI: 10.1111/his.15289
Rachelle A Wolk, Nicole A Cipriani

With the advancement of molecular testing and the routine use of immunohistochemical stains, salivary gland tumours previously categorized as adenoma or adenocarcinoma, not otherwise specified, are being reclassified with distinct diagnoses. Newly recognized benign entities include: sclerosing polycystic adenoma, keratocystoma, intercalated duct hyperplasia and adenoma, and striated duct adenoma. Newly recognized malignant salivary gland tumours include: microsecretory adenocarcinoma, sclerosing microcytic adenocarcinoma, and mucinous adenocarcinoma. Additionally, rare subtypes of mucoepidermoid carcinoma have been described, including Warthin-like and oncocytic. Understanding of intraductal carcinoma continues to evolve. Correctly distinguishing these lesions from mimickers can be crucial for appropriate patient care and prognostication, as well as future conceptualization of salivary disease.

随着分子检测技术的进步和免疫组化染色法的常规使用,以前被归类为腺瘤或腺癌(未另作说明)的唾液腺肿瘤正在被重新归类,作出不同的诊断。新发现的良性实体包括:硬化性多囊腺瘤、角化囊肿、闰管增生和腺瘤以及横纹导管腺瘤。新发现的恶性唾液腺肿瘤包括:微分泌性腺癌、硬化性微囊腺癌和粘液腺癌。此外,还描述了粘液表皮样癌的罕见亚型,包括华氏样癌和肿瘤细胞癌。人们对导管内癌的认识仍在不断发展。正确区分这些病变和模仿者对于适当的患者护理和预后以及未来唾液疾病的概念化至关重要。
{"title":"Update of newly-recognized salivary gland neoplasms: molecular and immunohistochemical findings and clinical importance.","authors":"Rachelle A Wolk, Nicole A Cipriani","doi":"10.1111/his.15289","DOIUrl":"https://doi.org/10.1111/his.15289","url":null,"abstract":"<p><p>With the advancement of molecular testing and the routine use of immunohistochemical stains, salivary gland tumours previously categorized as adenoma or adenocarcinoma, not otherwise specified, are being reclassified with distinct diagnoses. Newly recognized benign entities include: sclerosing polycystic adenoma, keratocystoma, intercalated duct hyperplasia and adenoma, and striated duct adenoma. Newly recognized malignant salivary gland tumours include: microsecretory adenocarcinoma, sclerosing microcytic adenocarcinoma, and mucinous adenocarcinoma. Additionally, rare subtypes of mucoepidermoid carcinoma have been described, including Warthin-like and oncocytic. Understanding of intraductal carcinoma continues to evolve. Correctly distinguishing these lesions from mimickers can be crucial for appropriate patient care and prognostication, as well as future conceptualization of salivary disease.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control 集中前列腺切除术配合术中 NeuroSAFE 边缘评估可改善手术边缘控制。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-07 DOI: 10.1111/his.15291
Lisa J Kroon, Sebastiaan Remmers, Martijn B Busstra, Melanie Gan, Sjoerd Klaver, John B W Rietbergen, Margaretha A van der Slot, Eva Hollemans, Charlotte F Kweldam, Chris H Bangma, Monique J Roobol, Geert J L H van Leenders

Aims

To investigate the surgical margin status in patients with prostate cancer who underwent robot-assisted radical prostatectomy (RARP) with intraoperative neurovascular structure-adjacent frozen-section analysis (NeuroSAFE) and evaluate differences compared to patients who underwent radical prostatectomy without NeuroSAFE.

Patients and Methods

Between September 2018 and January 2021, 962 patients underwent centralized RARP with NeuroSAFE. A secondary resection was performed in case of a positive surgical margin (PSM) on intraoperative frozen section (IFS) analysis to convert a PSM into a negative surgical margin (NSM). A retrospective cohort consisted of 835 patients who had undergone radical prostatectomy in a tertiary centre without NeuroSAFE between January 2000 and December 2017. We performed multivariable logistic regression to evaluate differences in risk of PSM between cohorts after controlling for clinicopathological variables.

Results

Patients operated with NeuroSAFE in the centralized clinic had 29% PSM at a definitive pathological RP examination. The median cumulative length of definitive PSM was 1.1 mm (interquartile range: 0.4–3.8). Among 275 men with PSM, 136 (49%) had a cumulative length ≤1 mm and 198 (72%) ≤3 mm. After controlling for PSA, Grade group, cribriform pattern, pT-stage, and pN-stage, patients treated in the centralized clinic with NeuroSAFE had significantly lower odds on PSM (odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.56–0.88; P = 0.002), PSM length >1 mm (OR: 0.14, 95% CI: 0.09–0.22; P < 0.001), and >3 mm (OR: 0.21, 95% CI: 0.14–0.30; P < 0.001).

Conclusion

This study provides a detailed overview of surgical margin status in a centralized RP NeuroSAFE cohort. Centralization with NeuroSAFE was associated with lower PSM rates and significantly shorter PSM cumulative lengths, indicating improved control of surgical margin status.

目的:研究接受机器人辅助前列腺癌根治术(RARP)并进行术中神经血管结构-邻近冰冻切片分析(NeuroSAFE)的前列腺癌患者的手术切缘状态,并评估与未进行NeuroSAFE的前列腺癌根治术患者相比的差异:2018年9月至2021年1月期间,962名患者接受了带有NeuroSAFE的集中式RARP。如果术中冰冻切片(IFS)分析显示手术切缘(PSM)阳性,则进行二次切除,将PSM转化为手术切缘阴性(NSM)。回顾性队列包括2000年1月至2017年12月期间在没有NeuroSAFE的三级中心接受根治性前列腺切除术的835名患者。在控制临床病理变量后,我们进行了多变量逻辑回归,以评估不同队列间PSM风险的差异:在集中诊所接受NeuroSAFE手术的患者中,有29%在进行最终病理RP检查时出现PSM。明确的 PSM 累积长度中位数为 1.1 毫米(四分位间范围:0.4-3.8)。在 275 名 PSM 患者中,136 人(49%)的累积长度≤1 毫米,198 人(72%)≤3 毫米。在控制了 PSA、分级组别、楔形模式、pT 分期和 pN 分期后,在 NeuroSAFE 中心化诊所接受治疗的患者 PSM 的几率显著降低(比值比 [OR]:0.70,95% 置信区间 [CI]:0.56-0.88;P = 0.002),PSM 长度 >1 mm(OR:0.14,95% CI:0.09-0.22;P 3 mm(OR:0.21,95% CI:0.14-0.30;P 结论:本研究提供了集中式 RP NeuroSAFE 队列中手术边缘状态的详细概述。NeuroSAFE集中化与较低的PSM率和显著缩短的PSM累积长度相关,表明对手术边缘状态的控制有所改善。
{"title":"Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control","authors":"Lisa J Kroon,&nbsp;Sebastiaan Remmers,&nbsp;Martijn B Busstra,&nbsp;Melanie Gan,&nbsp;Sjoerd Klaver,&nbsp;John B W Rietbergen,&nbsp;Margaretha A van der Slot,&nbsp;Eva Hollemans,&nbsp;Charlotte F Kweldam,&nbsp;Chris H Bangma,&nbsp;Monique J Roobol,&nbsp;Geert J L H van Leenders","doi":"10.1111/his.15291","DOIUrl":"10.1111/his.15291","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To investigate the surgical margin status in patients with prostate cancer who underwent robot-assisted radical prostatectomy (RARP) with intraoperative neurovascular structure-adjacent frozen-section analysis (NeuroSAFE) and evaluate differences compared to patients who underwent radical prostatectomy without NeuroSAFE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>Between September 2018 and January 2021, 962 patients underwent centralized RARP with NeuroSAFE. A secondary resection was performed in case of a positive surgical margin (PSM) on intraoperative frozen section (IFS) analysis to convert a PSM into a negative surgical margin (NSM). A retrospective cohort consisted of 835 patients who had undergone radical prostatectomy in a tertiary centre without NeuroSAFE between January 2000 and December 2017. We performed multivariable logistic regression to evaluate differences in risk of PSM between cohorts after controlling for clinicopathological variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients operated with NeuroSAFE in the centralized clinic had 29% PSM at a definitive pathological RP examination. The median cumulative length of definitive PSM was 1.1 mm (interquartile range: 0.4–3.8). Among 275 men with PSM, 136 (49%) had a cumulative length ≤1 mm and 198 (72%) ≤3 mm. After controlling for PSA, Grade group, cribriform pattern, pT-stage, and pN-stage, patients treated in the centralized clinic with NeuroSAFE had significantly lower odds on PSM (odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.56–0.88; <i>P</i> = 0.002), PSM length &gt;1 mm (OR: 0.14, 95% CI: 0.09–0.22; <i>P</i> &lt; 0.001), and &gt;3 mm (OR: 0.21, 95% CI: 0.14–0.30; <i>P</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides a detailed overview of surgical margin status in a centralized RP NeuroSAFE cohort. Centralization with NeuroSAFE was associated with lower PSM rates and significantly shorter PSM cumulative lengths, indicating improved control of surgical margin status.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 5","pages":"760-768"},"PeriodicalIF":3.9,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.15291","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epithelial misplacement in Peutz–Jeghers polyps—the efficacy of the distribution of immunohistochemical markers in its diagnosis Peutz-Jeghers 息肉中的上皮错位--免疫组化标记物分布在诊断中的功效。
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-07 DOI: 10.1111/his.15293
Neil A Shepherd, Newton A C S Wong, Kieran Sheahan
{"title":"Epithelial misplacement in Peutz–Jeghers polyps—the efficacy of the distribution of immunohistochemical markers in its diagnosis","authors":"Neil A Shepherd,&nbsp;Newton A C S Wong,&nbsp;Kieran Sheahan","doi":"10.1111/his.15293","DOIUrl":"10.1111/his.15293","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 4","pages":"686-689"},"PeriodicalIF":3.9,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does the extent of extraprostatic extension at radical prostatectomy predict outcome?—a systematic review and meta-analysis 根治性前列腺切除术时前列腺外延伸的程度是否能预测手术效果?
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-07 DOI: 10.1111/his.15292
Lucia Lazzereschi, Jacqueline Birks, Richard Colling

Extraprostatic extension (EPE) of prostate cancer is usually reported as either focal (F-EPE) or established (E-EPE), but data on the implication for outcomes of this subdivision are conflicting and no systematic review (SR) evaluating this exists. This SR aims to address this gap in the literature, focusing on the impact of F-EPE and E-EPE on outcome in radical prostatectomy (RP) patients. Searches on Embase, Medline(R), and Pubmed databases were conducted. Studies were included if they investigated the extent of EPE in RP patients and correlated this with defined outcomes (biochemical recurrence [BCR], death, metastasis). Quality was assessed using the Newcastle-Ottawa Scale. A random effects model was used for studies reporting hazard ratios (EPE extent and biochemical recurrence). 24 studies, including 49,187 men, were included. Six studies were of high quality. 20 studies reported how they measured EPE. 13 studies reported that the extent of EPE was associated significantly with BCR. Meta-analysis showed there was a significant correlation between BCR and both F-EPE and E-EPE when compared to organ-confined disease; no significant difference was found between F-EPE and E-EPE. This is the only SR to investigate the extent of EPE on outcomes after RP. EPE alone predicts outcome, but the value of subdivision by extent could not be demonstrated. Comparisons are limited due to variability in EPE assessment and in the methods used to report outcomes in the literature. Further work to standardize EPE reporting methods, in larger cohorts, may be helpful to resolve remaining questions.

前列腺癌的前列腺外延伸(EPE)通常被报告为病灶性(F-EPE)或已确立的(E-EPE),但有关该分支对预后影响的数据却相互矛盾,也没有系统性综述(SR)对此进行评估。本SR旨在填补这一文献空白,重点研究F-EPE和E-EPE对根治性前列腺切除术(RP)患者预后的影响。我们在 Embase、Medline(R) 和 Pubmed 数据库中进行了检索。如果研究调查了 RP 患者 EPE 的程度,并将其与定义的结果(生化复发 [BCR]、死亡、转移)相关联,则纳入研究。研究质量采用纽卡斯尔-渥太华量表进行评估。随机效应模型用于报告危险比(EPE程度和生化复发)的研究。共纳入 24 项研究,包括 49,187 名男性。其中六项研究的质量较高。20 项研究报告了如何测量 EPE。13 项研究报告了 EPE 的程度与 BCR 有显著相关性。Meta 分析表明,与器官封闭性疾病相比,BCR 与 F-EPE 和 E-EPE 之间存在显著相关性;F-EPE 和 E-EPE 之间无显著差异。这是研究 EPE 对 RP 后预后影响程度的唯一 SR。单纯 EPE 可预测预后,但按程度细分的价值无法体现。由于 EPE 评估和文献中用于报告结果的方法存在差异,因此比较结果有限。在更大的队列中进一步开展标准化 EPE 报告方法的工作可能有助于解决剩余的问题。
{"title":"Does the extent of extraprostatic extension at radical prostatectomy predict outcome?—a systematic review and meta-analysis","authors":"Lucia Lazzereschi,&nbsp;Jacqueline Birks,&nbsp;Richard Colling","doi":"10.1111/his.15292","DOIUrl":"10.1111/his.15292","url":null,"abstract":"<p>Extraprostatic extension (EPE) of prostate cancer is usually reported as either focal (F-EPE) or established (E-EPE), but data on the implication for outcomes of this subdivision are conflicting and no systematic review (SR) evaluating this exists. This SR aims to address this gap in the literature, focusing on the impact of F-EPE and E-EPE on outcome in radical prostatectomy (RP) patients. Searches on Embase, Medline(R), and Pubmed databases were conducted. Studies were included if they investigated the extent of EPE in RP patients and correlated this with defined outcomes (biochemical recurrence [BCR], death, metastasis). Quality was assessed using the Newcastle-Ottawa Scale. A random effects model was used for studies reporting hazard ratios (EPE extent and biochemical recurrence). 24 studies, including 49,187 men, were included. Six studies were of high quality. 20 studies reported how they measured EPE. 13 studies reported that the extent of EPE was associated significantly with BCR. Meta-analysis showed there was a significant correlation between BCR and both F-EPE and E-EPE when compared to organ-confined disease; no significant difference was found between F-EPE and E-EPE. This is the only SR to investigate the extent of EPE on outcomes after RP. EPE alone predicts outcome, but the value of subdivision by extent could not be demonstrated. Comparisons are limited due to variability in EPE assessment and in the methods used to report outcomes in the literature. Further work to standardize EPE reporting methods, in larger cohorts, may be helpful to resolve remaining questions.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 5","pages":"727-742"},"PeriodicalIF":3.9,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.15292","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative margin assessment during radical prostatectomy: is microscopy frozen in time or ready for digital defrost? 根治性前列腺切除术中的术中边缘评估:显微镜是及时冻结还是准备数字解冻?
IF 3.9 2区 医学 Q2 CELL BIOLOGY Pub Date : 2024-08-05 DOI: 10.1111/his.15290
Eoin Dinneen, Ricardo Almeida-Magana, Tarek Al-Hammouri, Iona Fernandes, Nikhil Mayor, Larissa Mendes, Mathias Winkler, Anna Silvanto, Aiman Haider, Alex Freeman, Greg Shaw

Intraoperative frozen section (IFS) is used with the intention to improve functional and oncological outcomes for patients undergoing radical prostatectomy (RP). High resource requirements of IFS techniques such as NeuroSAFE may preclude widespread adoption, even if there are benefits to patients. Recent advances in fresh-tissue microscopic digital imaging technologies may offer an attractive alternative, and there is a growing body of evidence regarding these technologies. In this narrative review, we discuss some of the familiar limitations of IFS and compare these to the attractive counterpoints of modern digital imaging technologies such as the speed and ease of image generation, the locality of equipment within (or near) the operating room, the ability to maintain tissue integrity, and digital transfer of images. Confocal laser microscopy (CLM) is the modality most frequently reported in the literature for margin assessment during RP. We discuss several imitations and obstacles to widespread dissemination of digital imaging technologies. Among these, we consider how the ‘en-face’ margin perspective will challenge urologists and pathologists to understand afresh the meaning of positive margin significance. As a part of this, discussions on how to describe, categorize, react to, and evaluate these technologies are needed to improve patient outcomes. Limitations of this review include its narrative structure and that the evidence base in this field is relatively immature but developing at pace.

使用术中冰冻切片(IFS)的目的是为了改善根治性前列腺切除术(RP)患者的功能和肿瘤治疗效果。神经前列腺电切术(NeuroSAFE)等术中冷冻切片技术需要大量资源,即使能为患者带来益处,也可能无法得到广泛应用。新鲜组织显微数字成像技术的最新进展可能会提供一种有吸引力的替代方案,而且有关这些技术的证据也在不断增加。在这篇叙述性综述中,我们将讨论人们所熟悉的 IFS 的一些局限性,并将其与现代数字成像技术的诱人之处进行比较,如图像生成的速度和简易性、设备在手术室内(或附近)的位置、保持组织完整性的能力以及图像的数字传输。共焦激光显微镜(CLM)是文献中最常报道的用于 RP 期间边缘评估的方式。我们讨论了数字成像技术在广泛推广过程中的一些模仿和障碍。其中,我们考虑了 "正视 "边缘视角将如何挑战泌尿科医生和病理学家重新理解边缘阳性意义。作为其中的一部分,我们需要讨论如何描述、分类、应对和评估这些技术,以改善患者的治疗效果。本综述的局限性包括其叙述性结构,以及该领域的证据基础相对不成熟,但发展速度较快。
{"title":"Intraoperative margin assessment during radical prostatectomy: is microscopy frozen in time or ready for digital defrost?","authors":"Eoin Dinneen,&nbsp;Ricardo Almeida-Magana,&nbsp;Tarek Al-Hammouri,&nbsp;Iona Fernandes,&nbsp;Nikhil Mayor,&nbsp;Larissa Mendes,&nbsp;Mathias Winkler,&nbsp;Anna Silvanto,&nbsp;Aiman Haider,&nbsp;Alex Freeman,&nbsp;Greg Shaw","doi":"10.1111/his.15290","DOIUrl":"10.1111/his.15290","url":null,"abstract":"<p>Intraoperative frozen section (IFS) is used with the intention to improve functional and oncological outcomes for patients undergoing radical prostatectomy (RP). High resource requirements of IFS techniques such as NeuroSAFE may preclude widespread adoption, even if there are benefits to patients. Recent advances in fresh-tissue microscopic digital imaging technologies may offer an attractive alternative, and there is a growing body of evidence regarding these technologies. In this narrative review, we discuss some of the familiar limitations of IFS and compare these to the attractive counterpoints of modern digital imaging technologies such as the speed and ease of image generation, the locality of equipment within (or near) the operating room, the ability to maintain tissue integrity, and digital transfer of images. Confocal laser microscopy (CLM) is the modality most frequently reported in the literature for margin assessment during RP. We discuss several imitations and obstacles to widespread dissemination of digital imaging technologies. Among these, we consider how the ‘<i>en-face</i>’ margin perspective will challenge urologists and pathologists to understand afresh the meaning of positive margin significance. As a part of this, discussions on how to describe, categorize, react to, and evaluate these technologies are needed to improve patient outcomes. Limitations of this review include its narrative structure and that the evidence base in this field is relatively immature but developing at pace.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 5","pages":"716-726"},"PeriodicalIF":3.9,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.15290","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Histopathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1